Rajiv De Silva

Rajiv De Silva is a declared insider at 6 companies; the most frequent names are Valeant Pharmaceuticals International, Inc., Endo International plc and Valeant Pharmaceuticals International. We count 70 filings; the first trade dates from 1 June 2001 and the latest from 18 November 2022.

Both buying and selling appear: 7 purchases worth €1.3M, against 8 sales worth €18.0M. No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 34 share grants and 15 option exercises. So far in 2022, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €167k.

The record was last updated on 22 November 2022 with an open-market purchase (€241k) in Venus Concept Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.